PH-797804

Generic Name: PH-797804

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₁₉BrF_₂N_₂O_₃

CAS Number: 586379-66-0

Unique Ingredient Identifier: SI09I1V827

Background: PH-797804 has been investigated for the treatment of Osteoarthritis.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

PH-797804 LPS Study in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Drug: PH-797804

First Posted Date: 2014-03-12

Last Posted Date: 2014-03-14

Lead Sponsor: Pfizer

Target Recruit Count: 24

Registration Number: NCT02084485

Locations: 🇬🇧
Pfizer Investigational Site, Denmark Hill, London, United Kingdom

A Pharmacokinetic Study of Three Different Particle Sizes of PH-797804

Phase 1

Withdrawn

Conditions: Healthy

Interventions: Drug: PH-797804

First Posted Date: 2013-08-16

Last Posted Date: 2013-12-20

Lead Sponsor: Pfizer

Registration Number: NCT01924650

A Study to Investigate the Effect of PH-797804 on QTc Interval

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: PH-797804
Drug: Placebo
Drug: Moxifloxacin

First Posted Date: 2013-05-27

Last Posted Date: 2013-08-15

Lead Sponsor: Pfizer

Target Recruit Count: 48

Registration Number: NCT01862887

Locations: 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States

A Study To Investigate The Effect Of Erythromycin On The Pharmacokinetics Of PH-797804

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: PH-797804 + erythromycin
Drug: PH-797804

First Posted Date: 2012-05-02

Last Posted Date: 2012-08-17

Lead Sponsor: Pfizer

Target Recruit Count: 12

Registration Number: NCT01589614

Locations: 🇸🇬
Pfizer Investigational Site, Singapore, Singapore

Study To Evaluate The Efficacy And Safety Of PH-797804 For 12 Weeks In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD) On A Background Of Tiotropium Bromide

Phase 2

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Placebo
Drug: PH-797804

First Posted Date: 2012-03-05

Last Posted Date: 2014-10-27

Lead Sponsor: Pfizer

Target Recruit Count: 730

Registration Number: NCT01543919

Locations: 🇨🇳
Pfizer Investigational Site, Taipei, Taiwan

A Study To Investigate The Effect Of Food On The Pharmacokinetics Of PH-797804

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: PH-797804

First Posted Date: 2011-11-24

Last Posted Date: 2012-02-28

Lead Sponsor: Pfizer

Target Recruit Count: 28

Registration Number: NCT01479647

Locations: 🇸🇬
Pfizer Investigational Site, Singapore, Singapore

Study To Evaluate The Efficacy And Safety Of PH-797804 For 12 Weeks In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD) Taking Salmeterol Xinafoate/Fluticasone Propionate Combination

Phase 2

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: PH-797804
Drug: Placebo

First Posted Date: 2011-03-23

Last Posted Date: 2013-07-11

Lead Sponsor: Pfizer

Target Recruit Count: 377

Registration Number: NCT01321463

Locations: 🇬🇧
Pfizer Investigational Site, Glasgow, United Kingdom

Single Dose Lipopolysaccharide (LPS) Study In Healthy Volunteers

Phase 1

Completed

Conditions: Chronic Obstructive Pulmonary Disease (COPD)

Interventions: Drug: PF-03715455
Drug: Placebo for PF-03715455
Drug: Placebo for PH-797804
Drug: PH-797804

First Posted Date: 2011-03-15

Last Posted Date: 2012-02-02

Lead Sponsor: Pfizer

Target Recruit Count: 39

Registration Number: NCT01314885

Locations: 🇬🇧
Pfizer Investigational Site, Manchester, United Kingdom

Clinical Trial to Examine the Pain Relief of PH-797804 Alone Or With Naproxen in Subjects With Osteoarthritis of the Knee

Phase 2

Completed

Conditions: Osteoarthritis

Interventions: Drug: Naproxen + PH-797804
Drug: PH-797804
Drug: Placebo
Drug: Naproxen

First Posted Date: 2010-04-13

Last Posted Date: 2014-08-22

Lead Sponsor: Pfizer

Target Recruit Count: 172

Registration Number: NCT01102660

Locations: 🇺🇸
Pfizer Investigational Site, San Antonio, Texas, United States

A Study To Evaluate The Safety And Pharmacokinetic Profile Of A P38 Inhibitor (PH-797804) In Subjects With Rheumatoid Arthritis Who Are Also Taking Methotrexate

Phase 2

Completed

Conditions: Arthritis, Rheumatoid

Interventions: Drug: Placebo
Drug: PH-797804

First Posted Date: 2008-02-21

Last Posted Date: 2018-11-08

Lead Sponsor: Pfizer

Target Recruit Count: 27

Registration Number: NCT00620685

Locations: 🇺🇸
Pfizer Investigational Site, Duncansville, Pennsylvania, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy